Korea University Anam Hospital
No hidden fees – just official clinic prices. Pay at the clinic for Desmoid Tumor treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Desmoid Tumor treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Desmoid Tumor treatment journey.
Active surveillance is the preferred initial treatment for desmoid tumours in Korea. Specialists use MRI or CT scans every 8 to 12 weeks to monitor stable or asymptomatic tumours. This non-invasive approach avoids surgery. 30% of these tumours shrink or stabilise without intervention.
Bookimed Expert Insight: Major Seoul centres like Korea University Anam Hospital manage over 1.3 million patients annually. Their high volume supports a multidisciplinary approach where oncology and surgery departments collaborate daily. Patients benefit from same-day consultations. This speed is vital for baseline imaging before starting surveillance cycles.
Patient Consensus: Patients emphasise starting with watch-and-wait strategies because many tumours stop growing naturally. They recommend asking about oral targeted therapies in Korea before considering surgery. These drugs can preserve organ function.
Patients definitely need a sarcoma specialist for desmoid tumours in South Korea. These rare tumours have high recurrence rates. Specialist teams at facilities like Korea University Anam Hospital use multidisciplinary reviews. This provides tailored treatment using active surveillance or targeted therapies instead of immediate surgery.
Bookimed Expert Insight: Korea University Anam Hospital serves over 1,300,000 patients annually. They offer same-day consultations and tests for new cancer cases. This speed is vital for desmoid tumours that require quick biopsy results. Their 5 consecutive JCI accreditations signal high safety standards for complex tumour management.
Patient Consensus: Individuals note that surgery remains a last resort because even clear margins rarely prevent regrowth. They suggest finding a Korean clinician who discusses non-surgical options like cryoablation or observation first.
Desmoid tumour recurrence in Korea typically ranges from 25% to 60% after treatment. Surgeons often achieve complete removal, yet recurrence risk remains between 15% and 30%. Korean specialists now favour active surveillance and targeted therapies. They prefer these over immediate surgery to manage these risks.
Bookimed Expert Insight: Major Korean centres like Korea University Anam Hospital manage over 1,300,000 patients annually. They use multi-speciality teams to decide between surgery and surveillance. Patients benefit from same-day consultations and tests. This speed helps catch recurrence early when it is easiest to treat.
Patient Consensus: Patients note that surgery is often a last resort. Repeat operations can raise recurrence risks. They emphasise that the first year is the most critical time for regular scans. This applies in Korea.
South Korean hospitals offer non-surgical desmoid tumour treatments including targeted drug therapies and real-time MRI-guided radiation. Recognised JCI-accredited centres provide multidisciplinary sarcoma care. They use precise technologies like Elekta Unity MR-Linac. This spares healthy tissue during intensive radiation protocols. Recovery times often remain short.
Bookimed Expert Insight: Korea University Anam Hospital serves over 1 million patients annually. Our data shows their capacity for bloodless surgery options speeds recovery significantly. This high volume allows their 570 doctors to refine non-surgical protocols for complex cases. Australian patients benefit from JCI-accredited safety standards in Seoul.
Patient Consensus: Patients note that active surveillance is often the best first step for stable tumours. They emphasise seeking a sarcoma specialist to discuss targeted drugs like sorafenib or nirogacestat rather than rushing into surgery in Korea.
The latest targeted therapy for desmoid tumours is nirogacestat, a gamma-secretase inhibitor. While approved internationally, it is currently accessed in Korea primarily via clinical trials. Specialised centres such as Korea University Anam Hospital manage complex oncology cases. They use established alternatives like tyrosine kinase inhibitors.
Bookimed Expert Insight: Korea University Anam Hospital serves over 114,000 monthly outpatients and offers same-day consultations. This speed is vital for desmoid cases where tumours progress quickly. Their experience with 20,000+ monthly surgeries allows quick intervention if drug therapy alone proves insufficient.
Patient Consensus: Patients note that sorafenib remains the practical local choice in Korea for shrinking large tumours. Many suggest consulting sarcoma specialists. Stable desmoids often require simple observation rather than immediate surgery.
Patients choosing active surveillance in Korea usually undergo monitoring every 3 to 6 months. This desmoid tumour protocol includes clinical exams and MRI scans. Korean centres such as Korea University Anam Hospital use high-volume oncology units to track stability. Intervals often extend after 2 years.
Bookimed Expert Insight: Major Seoul hospitals like Korea University Anam serve over 1,300,000 patients annually. Their oncology departments often provide same-day consultations and tests. This speed helps international patients confirm their monitoring schedule quickly before returning home. Efficiency at these JCI-accredited hubs means stability is documented accurately from the first visit.
Patient Consensus: Patients note that 6-monthly MRIs are common once a desmoid tumour stabilises. Many mention that monitoring becomes more frequent if pain or growth occurs. In Korea, the practical focus is often on whether scans can be reviewed remotely later.